Mitochondrial Complex Iv (Cytochrome C Oxidase) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Mitochondrial Complex IV, also known as Cytochrome c Oxidase (COX) or Terminal Oxidase, is the terminal enzyme of the Electron Transport Chain (ETC). It catalyzes the transfer of four electrons from cytochrome c to molecular oxygen (O2), reducing it to two molecules of water (H2O). This reaction is coupled with the pumping of protons across the inner mitochondrial membrane, contributing to the establishment of the proton gradient that drives ATP synthesis. [1]
Complex IV represents the final and most energetically favorable step of oxidative phosphorylation. It is one of the key coupling sites where electron transfer is linked to proton pumping. The efficient function of Complex IV is essential for cellular ATP production, and its dysfunction has been strongly implicated in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Leigh syndrome. [2]
Complex IV is composed of 13 subunits in mammals, forming a symmetric dimer: [3]
The catalytic mechanism of Complex IV involves a carefully choreographed series of electron transfers and proton movements: [4]
Cytochrome c → CuA → Heme a → Heme a3-CuB → O2
Complex IV assembly requires numerous assembly factors: [5]
Mutations in assembly factors cause severe mitochondrial disorders. [6]
Complex IV deficiency is one of the most consistent mitochondrial abnormalities in AD: [7]
Evidence: Immunohistochemical studies show reduced COX expression in vulnerable brain regions. Genetic studies have identified rare variants in COX genes that may modify AD risk. [8]
Complex IV has a complex relationship with PD: [9]
Evidence: While Complex I deficiency is the hallmark mitochondrial defect in PD, Complex IV dysfunction contributes to disease progression. [10]
The study of Mitochondrial Complex Iv (Cytochrome C Oxidase) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [11]
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [12]
🔴 Low Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 13 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |
Overall Confidence: 35%
Kadenbach B, Hüttemann M, Arnold S, Lee I, Bender E. Mitochondrial energy metabolism is regulated via nuclear-encoded subunits of cytochrome c oxidase. Free Radic Biol Med. 2000. ↩︎
Richter OM, Ludwig B. Cytochrome c oxidase - structure, function, and physiology of a redox-driven proton pump. Rev Physiol Biochem Pharmacol. 2003. ↩︎
Tsukihara T, Aoyama H, Yamashita E, et al. The whole structure of the 13-subunit oxidized cytochrome c oxidase at 2.8 Å. Science. 1996. ↩︎
Sazanov LA. A giant molecular proton pump in the respiratory chain. Biochim Biophys Acta. 2013. ↩︎
Castellani R, Hirai K, Aliev G, et al. Role of mitochondrial dysfunction in Alzheimer's disease. J Neurosci Res. 2002. ↩︎
Parker WD Jr, Filley CM, Parks JK. Complex I deficiency in Alzheimer's disease frontal cortex. J Neurochem. 1990. ↩︎
Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006. ↩︎
Schapira AH. Mitochondrial involvement in Parkinson's disease. Biochim Biophys Acta. 1998. ↩︎
Wallace DC. Mitochondrial diseases in man and mouse. Science. 1999. ↩︎
DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases. N Engl J Med. 2003. ↩︎
Zeviani M, Carelli V. Mitochondrial disorders. Curr Opin Neurol. 2007. ↩︎
Vyas S, Maniyadath B, Bhatt L. 'Targeting cytochrome c oxidase of mitochondria to combat neurodegeneration: an update'. Curr Top Med Chem. 2020. ↩︎